CoChat

Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings

Open access
Dichter, Gabriel S, Damiano, Cara A, Allen, John A · 2012 · Journal of Neurodevelopmental Disorders

The DOI matches its Crossref record; 778 of the 780 references it cites were found in a registry or an index; 71 of the 669 sources its claims cite were checked for support.

Abstract

This review summarizes evidence of dysregulated reward circuitry function in a range of neurodevelopmental and psychiatric disorders and genetic syndromes. First, the contribution of identifying a core mechanistic process across disparate disorders to disease classification is discussed, followed by a review of the neurobiology of reward circuitry. We next consider preclinical animal models and clinical evidence of reward-pathway dysfunction in a range of disorders, including psychiatric disorders (i.e., substance-use disorders, affective disorders, eating disorders, and obsessive compulsive disorders), neurodevelopmental disorders (i.e., schizophrenia, attention-deficit/hyperactivity disorder, autism spectrum disorders, Tourette's syndrome, conduct disorder/oppositional defiant disorder), and genetic syndromes (i.e., Fragile X syndrome, Prader-Willi syndrome, Williams syndrome, Angelman syndrome, and Rett syndrome). We also provide brief overviews of effective psychopharmacologic agents that have an effect on the dopamine system in these disorders. This review concludes with methodological considerations for future research designed to more clearly probe reward-circuitry dysfunction, with the ultimate goal of improved intervention strategies.

Overview

CoChat Summary

TL;DR

This narrative review argues that altered striatal dopamine reward-circuitry function is a shared neurobiological feature across substance-use, affective, eating, obsessive-compulsive, neurodevelopmental, and genetic syndromes, drawing on animal models and clinical functional/molecular imaging. It concludes that dopaminergic treatments may target this common dysfunction, but cross-sectional, standardized-reward studies and a DA-only focus limit etiologic and developmental inferences.

Key findings

  • In substance-use disorders, drug cues are associated with relative mesolimbic hyperactivation, while non-drug rewards often show reduced motivation; molecular imaging reports decreased D2 receptor binding in cocaine, heroin, alcohol, and methamphetamine abuse.
  • In major depressive disorder, behavioral and neuroimaging evidence indicates blunted reward response and hypoactivation in dorsal/ventral striatum and other reward regions; anhedonia may represent a trait marker in remitted MDD.
  • In ADHD, fMRI studies show decreased ventral striatum activation during monetary-reward anticipation, and DAT knockout and spontaneously hypertensive rat models implicate altered mesolimbic/mesostriatal DA transmission.
  • In ASD and genetic syndromes, findings are mixed or limited: ASD shows diminished ventral striatal response to social and monetary reward outcomes in some studies but unimpaired ERP reward markers in another; PWS shows hyperactivation to food cues; FXS, AS, RS, and WS lack direct reward fMRI or have only indirect/preclinical evidence.

Methods

  • Narrative review, not a systematic review or meta-analysis; it summarizes preclinical animal models and clinical studies, with emphasis on functional neuroimaging and molecular imaging of striatal DA transmission.
  • Disorders covered include psychiatric disorders (substance-use, affective, eating, OCD), neurodevelopmental disorders (schizophrenia, ADHD, ASD, TS, CD/ODD), and genetic syndromes (FXS, PWS, WS, AS, RS), plus brief overviews of dopaminergic treatments.
  • No new primary data are reported.

Limitations

  • The authors state that most clinical research is cross-sectional and adult-focused, limiting developmental and etiologic inferences; standardized rewards may not capture individual-specific or disorder-specific stimuli; and linking mesolimbic DA one-to-one with reward is overly simplistic because non-DA systems and other brain regions also contribute.
  • Evident from the text: the review is narrative without a systematic search or quantitative synthesis, and the evidence base is uneven—some conditions have very few or no direct reward neuroimaging studies (e.g., bipolar disorder had only three published functional neuroimaging studies of reward, TS had no published functional neuroimaging studies of response to rewards, AS had no functional brain-imaging data on rewards, and FXS had no functional brain-imaging studies of rewarding stimuli).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/1866-1955-4-19

Cites

778 of 778 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Schematic illustration of the DA pathways and circuitry that regulate dopamine (DA) release in the human brain. The DA-containing neurons in the ventral tegmental area (VTA)/substantia nigra (SN) project to the nucleus accumbens (mesolimbic pathway; orange), to the cortex (mesocortical pathway; yellow) and caudate putamen (nigrostriatal pathway; purple). DA neuron firing rates are maintained at tonic levels in part due to steady-state inhibitory firing from the ventral pallidum. Excitatory glutamatergic fibers (green) project from the prefrontal cortex, amygdala, and hippocampus, that synapse on striatal targets, including the nucleus accumbens (NAc). The NAc sends GABAergic projections (red) to the ventral pallidum that suppress ventral pallidum inhibition of the VTA, thereby facilitating phasic burst firing of ventral tegmental area DA neurons. Note: Placement of structures is only approximate. Amyg, amygdala; Caud, caudate; DA, dopamine; GABA, GABAergic projections; Glu, glutamatergic projections; Hipp, hippocampus; Put, putamen; VP, ventral pallidum. (Figure and legend adapted with permission from Treadway and Zald [19].)
Figure 1 Schematic illustration of the DA pathways and circuitry that regulate dopamine (DA) release in the human brain. The DA-containing neurons in the ventral tegmental area (VTA)/substantia nigra (SN) project to the nucleus accumbens (mesolimbic pathway; orange), to the cortex (mesocortical pathway; yellow) and caudate putamen (nigrostriatal pathway; purple). DA neuron firing rates are maintained at tonic levels in part due to steady-state inhibitory firing from the ventral pallidum. Excitatory glutamatergic fibers (green) project from the prefrontal cortex, amygdala, and hippocampus, that synapse on striatal targets, including the nucleus accumbens (NAc). The NAc sends GABAergic projections (red) to the ventral pallidum that suppress ventral pallidum inhibition of the VTA, thereby facilitating phasic burst firing of ventral tegmental area DA neurons. Note: Placement of structures is only approximate. Amyg, amygdala; Caud, caudate; DA, dopamine; GABA, GABAergic projections; Glu, glutamatergic projections; Hipp, hippocampus; Put, putamen; VP, ventral pallidum. (Figure and legend adapted with permission from Treadway and Zald [19].)CC BY · PubMed Central
Figure 2 Schematic illustration of cellular mechanisms of neurotransmission in the mesolimbic dopamine (DA) reward pathway. Shown is a synapse between a ventral tegmental area DA neuron axon terminal and a medium spiny neuron (MSN) in the nucleus accumbens (NAc) in the ventral striatum. Transmission begins with an action potential that arrives to the terminal, inducing synaptic vesicle fusion and release of DA. The release of DA into the NAc stimulates various populations of MSNs, whose response to the transmitter depends on the types of DA receptors they express. DA stimulation of neurons containing D1 or D5 receptors (so-called D1-like receptors) results in activation of heterotrimeric Golf/Gs proteins, which activate the enzyme adenylyl cyclase, resulting in the synthesis of the second messenger cAMP. In contrast to this mechanism, DA stimulation of MSNs that express D2, D3 or D4 (or D2-like receptors) activate sheterotrimeric Gi/Go proteins, which inhibit adenylyl cyclase activity to decrease cAMP. The level of intracellular cAMP controls the activation of protein kinase A, which regulates additional signaling molecules including dopamine- and cAMP-regulated neuronal phosphoprotein of 32 kDa (DARPP-32) and the transcription factor cAMP response element binding (CREB) protein, both of which can modulate gene expression and additional cellular responses. The response to DA is generally terminated when DA is removed from the synapse by reuptake via the DA transporter (DAT). After reuptake, the transmitter can be repackaged into synaptic vesicles or may be degraded by the enzyme monoamine oxidase, resulting in the DA metabolite homovanillic acid. In addition, the enzyme catechol-o-methyltransferase (COMT) may also control DA levels by breaking down DA to 3-methoxytyramine (3-MT), AC, adenylyl cyclase; ATP; adensosine triphosphate; cAMP; cyclic adenosine monophosphate; HVA, homovanillic acid; MAO, monoamine oxidase; VTA, ventral tegmental area.
Figure 2 Schematic illustration of cellular mechanisms of neurotransmission in the mesolimbic dopamine (DA) reward pathway. Shown is a synapse between a ventral tegmental area DA neuron axon terminal and a medium spiny neuron (MSN) in the nucleus accumbens (NAc) in the ventral striatum. Transmission begins with an action potential that arrives to the terminal, inducing synaptic vesicle fusion and release of DA. The release of DA into the NAc stimulates various populations of MSNs, whose response to the transmitter depends on the types of DA receptors they express. DA stimulation of neurons containing D1 or D5 receptors (so-called D1-like receptors) results in activation of heterotrimeric Golf/Gs proteins, which activate the enzyme adenylyl cyclase, resulting in the synthesis of the second messenger cAMP. In contrast to this mechanism, DA stimulation of MSNs that express D2, D3 or D4 (or D2-like receptors) activate sheterotrimeric Gi/Go proteins, which inhibit adenylyl cyclase activity to decrease cAMP. The level of intracellular cAMP controls the activation of protein kinase A, which regulates additional signaling molecules including dopamine- and cAMP-regulated neuronal phosphoprotein of 32 kDa (DARPP-32) and the transcription factor cAMP response element binding (CREB) protein, both of which can modulate gene expression and additional cellular responses. The response to DA is generally terminated when DA is removed from the synapse by reuptake via the DA transporter (DAT). After reuptake, the transmitter can be repackaged into synaptic vesicles or may be degraded by the enzyme monoamine oxidase, resulting in the DA metabolite homovanillic acid. In addition, the enzyme catechol-o-methyltransferase (COMT) may also control DA levels by breaking down DA to 3-methoxytyramine (3-MT), AC, adenylyl cyclase; ATP; adensosine triphosphate; cAMP; cyclic adenosine monophosphate; HVA, homovanillic acid; MAO, monoamine oxidase; VTA, ventral tegmental area.CC BY · PubMed Central

Verification

Claims the paper makes

49 Valid · 3 Not valid · 329 Not checked · 60 Own results and interpretations

223 more claims · 21 with their cited sources checked

Create a free account to see all 441 claims and to verify the 598 references still open.

See all claims — free account
  • It may state two separate claims as one. 191
  • Probably not a substantial claim. 43

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Show all 778 references

Research works printed but not linked: 5

  1. Buhler M, Vollstadt-Klein S, Kobiella A, Budde H, Reed LJ, Braus DF, Buchel C, Smolka MN: Nicotine Dependence Is Characterized by Disordered Reward Processing in a Network Driving Motivation. Biol Psychiatry. 2009
  2. Keedwell PA, Andrew C, Williams SCR, Brammer MJ, Zelaya F, Phillips ML: The neural correlates of depression. Biol Psychiatr. 2003, 53: 171S-
  3. Dichter GS, Tomarken AJ, Shelton RC, Freid C, Addington S: Effects of Bupropion SR on dimensions of mood. 2001, Poster presented at the annual meeting of The American Psychiatric Association, New Orleans, Louisiana
  4. Alexander W: Prozac wins new indication for bulimia nervosa. Drug Topics. 1997, 141 (6): 34-
  5. Rado S: Psychoanalysis of Behavior: The Collected Papers of Sandor Rado (Vol. 2). 1962, Grune & Stratton, New York

Cited by

See all 344

Metadata

Authors
Dichter, G. S., Damiano, C. A., & Allen, J. A.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • Pfizer (United States) (US)
Corresponding author
Dichter, Gabriel S
Venue
Journal of Neurodevelopmental Disorders
Published
2012-07-06
Volume
4
Issue
1
Pages
19-19
ISSN
  • 1866-1947 (ISSN-L)
  • 1866-1955
OpenAlex
W2108366837
Cited by
299
References
780
Citations by year
2026: 10 · 2025: 14 · 2024: 12 · 2023: 23 · 2022: 21 · 2021: 20 · 2020: 32 · 2019: 18 · 2018: 30 · 2017: 24 · 2016: 18 · 2015: 30 · 2014: 25 · 2013: 17 · 2012: 4
FWCI
10.02
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/2.0 (tdm)
Locations
  • Journal of Neurodevelopmental Disorders (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DukeSpace (Duke University) (submittedVersion, cc-by-nc-nd)
  • UNC Libraries
Funders
Autism Speaks
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
reward systems, dopaminergic system, mental illness, neurodevelopmental disorders, genetic syndromes, substance use disorders, mood disorders, eating disorders, obsessive-compulsive disorder, schizophrenia, attention deficit hyperactivity disorder, autism spectrum disorder, Tourette syndrome, conduct disorder, fragile X syndrome, Prader-Willi syndrome, Williams syndrome, Angelman syndrome, Rett syndrome, animal models, psychopharmacology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings. https://app.cochat.ai/papers/10.1186/1866-1955-4-19
The paper
Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012). Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings. Journal of Neurodevelopmental Disorders. https://doi.org/10.1186/1866-1955-4-19

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.